Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06189053 · ClinicalTrials.gov registry record
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)
A clinical trial of Myocarditis, sponsored by ModernaTX.
- Active
- Registry status
- 1,500
- Enrollment target
- 1
- Study location
NCT06189053 is a study of Myocarditis that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 1,500 participants, above the 88-participant average among 5 other Myocarditis trials with a reported enrollment target (1605% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06189053, a study of Myocarditis, is active but no longer recruiting, sponsored by ModernaTX.
- ACTIVE NOT RECRUITING
- Registry status
- 1,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.
Conditions Studied
Study Locations (1)
Illinois
- Veradigm - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,500 participants |
| Start Date | 2022-04-30 |
| Est. Completion | 2028-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06189053
The ClinicalTrials.gov registry entry for NCT06189053 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 5 other Myocarditis trials with a reported enrollment target (1605% higher). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myocarditis appearing as the primary indexed condition, and to 0 interventions.
NCT06189053 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT06189053 about?
NCT06189053 is a clinical study titled "A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)". The main goal of this study is to characterize presentation, clinical course, and long-term outcomes of myocarditis temporally associated with administration of mRNA-1273 (SPIKEVAX) COVID-19 vaccine.
What is the current status of trial NCT06189053?
This trial is currently active not recruiting. The enrollment target is 1,500 participants. The study started on 2022-04-30. Estimated completion is 2028-10-31.
What conditions does trial NCT06189053 study?
This clinical trial studies the following conditions: Myocarditis.
Who is sponsoring clinical trial NCT06189053?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06189053 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myocarditis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FDG-PET as an Imaging Modality to Diagnose and Risk Stratify Subclinical, Imaging Negative Ici-Myocarditis
RECRUITING
-
A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old.
RECRUITING · Phase 4
-
Role of Novel ILR in the Management of PVCs
RECRUITING
-
Phase II Randomized Study of Muromonab-CD3, Cyclosporine, Methylprednisolone, and Prednisone in Patients With Giant Cell Myocarditis
COMPLETED · Phase 2
-
Evaluation of MyoStrain™ in Clinical Practice
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.